The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Stoke Therapeutics Inc shares valued at $30,600,000 were sold by Skorpios Trust on Jun 04 ’25. At $10.20 per share, Skorpios Trust sold 3,000,000 shares. The insider’s holdings dropped to 3,906,181 shares worth approximately $46.17 million following the completion of this transaction.
Also, Ticho Barry sold 6,471 shares, netting a total of over 64,892 in proceeds. Following the sale of shares at $10.03 each, the insider now holds 25,782 shares.
Before that, Ticho Barry had sold 1,745 shares from its account. In a trade valued at $17,450, the CHIEF MEDICAL OFFICER traded Stoke Therapeutics Inc shares for $10.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,745 shares, worth approximately $0.38 million.
As published in their initiating research note from Chardan Capital Markets on December 20, 2024, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $24. As of March 26, 2024, TD Cowen has increased its “Market perform” rating to a “an Outperform” for STOK.
Analyzing STOK Stock Performance
On last trading session,, Stoke Therapeutics Inc [NASDAQ: STOK] rose 2.78% to $11.82. The stock’s lowest price that day was $11.38, but it reached a high of $11.855 in the same session. During the last five days, there has been a surge of approximately 8.64%. Over the course of the year, Stoke Therapeutics Inc shares have jumped approximately 7.16%.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
RSI (Relative Strength Index) is 74.20 on the 14-day chart, showing overbought technical sentiment.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.82 million shares to 12.03 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 12.84 million shares. A decline of -6.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 17.79 of the overall float, the days-to-cover ratio (short ratio) decline to 17.79.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 91.3% from the previous closing price of $11.50. Analysts anticipate Stoke Therapeutics Inc stock to reach 58 by 2025, with the lowest price target being 18. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2025.
